Beyond Meat Posts Mixed Results; CRISPR Therapeutics Tops Estimates
- August 08th, 2023
- 462 views
Beyond Meat, Inc. (Nasdaq: BYND) has reported a second-quarter 2023 loss of $0.83 per share, slightly better than the consensus estimated loss of $0.86 per share. However, quarterly revenues of $102.10 million fell short of the analysts' projected $108.40 million mark.
The company has revised its full-year 2023 outlook, forecasting net revenues within the range of approximately $360 million to $380 million, down from the prior projection of $375 million to $415 million. The consensus estimate for the period stands at $388.04 million in revenue.
$BYND was trading at $13.49 in after-hours, showing a decrease of $1.79 (-11.71%)
In other news, CRISPR Therapeutics AG (Nasdaq: CRSP) has announced its second-quarter 2023 financial results, revealing a loss of $0.98 per share and revenues of $70.0 million. These figures surpassed market consensus estimates, which had anticipated a loss of $2.12 per share on revenue of $1.71 million.
In after-hours, $CRSP was trading at $49.10, up $0.76 (+1.57%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login